MiNK Therapeutics highlights Phase 2 trial testing agenT-797 with botensilimab and balstilimab in MSS colorectal cancer liver metastases

• MiNK Therapeutics flagged new preclinical data for agenT-797 in checkpoint inhibitor-refractory colorectal cancer liver metastases.
• Results will be presented at SITC’s 41st Annual Meeting on Nov. 7, 2026, using a human organoid model.
• Study points to tumor-cell killing with agenT-797 alone, supporting a Phase 2 combination trial in previously treated MSS metastatic colorectal cancer.
• Separate preclinical findings will be presented Nov. 6, 2026, showing iNKT approaches clearing senescent tumor cells and fibroblasts.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610020900PRIMZONEFULLFEED9838266) on October 02, 2026, and is solely responsible for the information contained therein.